1-4 of 4
Stephen Joseph Shuttleworth, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Eric Davis, MD, Felipe Samaniego, MD, Nathan H Fowler, MD, Jason R. Westin, MD, Hun Ju Lee, Michael Wang, MD, Fredrick B. Hagemeister, MD, Philip Beer, MD PhD, Alexander R. L. Cecil, James Dow, Duncan McHale, Franck Silva, Penny Ward, Arash Yavari, Stephen Joseph Shuttleworth, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4099.
https://doi.org/10.1182/blood-2019-130401
Published: 2019
Journal Articles

Pre-Clinical Evaluation of the PI3K-p110β/δ Inhibitor KA2237 in Mantle Cell Lymphoma

Shengjian Huang, Loretta J. Nastoupil, MD, Hui Guo, MD PhD, Taylor Bell, Makhdum Ahmed, MD MPH, Carrie J Li, Jack Wang, Yang Liu, PhD, Victoria Zhang, Caroline R Kim, Jordan N Boyle, Elizabeth A Lorence, Laura T Lam, PhD, Zhihong Chen, Hui Zhang, Stephen Joseph Shuttleworth, PhD, Krystle Nomie, PhD, Michael Wang, MD, Liang Zhang, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1837.
https://doi.org/10.1182/blood.V128.22.1837.1837
Published: 2016
Journal Articles

Felipe Samaniego

Neeraj Jain, PhD, Lalit Sehgal, PhD, R. Eric Davis, MD, Stephen Joseph Shuttleworth, PhD, Felipe Samaniego, MD
Journal: Blood
Blood (2016) 128 (22): 5145.
https://doi.org/10.1182/blood.V128.22.5145.5145
Published: 2016
Journal Articles

Design and Development of a Novel Orally-Active, PI3K-p110Beta/Delta Inhibitor with Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity

Stephen Joseph Shuttleworth, PhD
Journal: Blood
Blood (2015) 126 (23): 2052.
https://doi.org/10.1182/blood.V126.23.2052.2052
Published: 2015